Carr Auditorium + Zoom
Keynote
Promises and Pitfalls of Technology in TB: the Ongoing Story of Video Directly Observed Therapy in the U.S.
Neela D. Goswami, MD, MPH
Medical Officer, Field Services Branch
Division of TB Elimination, NCHHSTP
U.S. Centers for Disease Control and Prevention
Neela Goswami serves as Senior Medical Officer in the Division of Tuberculosis (TB) Elimination at the U.S. Centers for Disease Control and Prevention. She also holds faculty appointments at Emory School of Medicine and Rollins School of Public Health and is an infectious diseases attending at the Grady Memorial Hospital Ponce de Leon HIV/AIDS clinic in Atlanta, GA. She oversees medical activities by the U.S. TB Centers of Excellence and serves as a resource for TB clinicians and staff as well as for various CDC branches on TB clinical issues. She has authored over 50 peer-reviewed publications and contributed to the development of several clinical and public health national guidelines in the areas of drug-resistant and drug-susceptible TB, HIV-TB, and COVID-19.
Payam Nahid, MD, MPH
Professor of Medicine, University of California, San Francisco
Director, UCSF Center for Tuberculosis
Co-Director, UCSF-UC Berkeley Tuberculosis Research Advancement Center (UC TRAC)
Director, Clinical Trials Operations, UCSF Office of Research
Medical Director, UCSF CTSI Trials Innovation Network (TIN)
Payam Nahid, MD, MPH, is a Professor in the Division of Pulmonary and Critical Care Medicine, Director of the UCSF Center for Tuberculosis, Co-Director of the UCSF-UC Berkeley Tuberculosis Research Advancement Center, Director of Clinical Trials Operations in the UCSF Office of Research, and Medical Director of the UCSF CTSA Trials Innovation Network Hub. His research includes the conduct of clinical trials and translational research in TB, and he leads NIH-funded field studies of new TB diagnostics, Phase 2 and 3 clinical trials in TB therapeutics and latent TB infection treatment implementation studies. Dr. Nahid serves as the Senior Scientific Advisor to the USAID-funded SMART4TB Consortium and led the WHO Task Force for New TB Drugs and Treatment Regimens, chairing the development of U.S. and international practice guidelines for the treatment of TB. Dr. Nahid serves as Vice Chair of the TB Transformative Science Group of the NIH ACTG, is a member of the ACTG leadership, and serves on the Scientific Agenda Steering Committee. Dr. Nahid was Co-Chair of the 2021 Phase 3 4-month rifapentine-based short-course treatment regimen and oversees NIH and BMGF-funded TB biomarker discovery and qualification programs to identify improved biomarkers of treatment effect.
CFAR Science Spotlight
UCSF Center for Tuberculosis Overview Programs, resources and opportunities for engagement for Early-Career and New-to-TB investigators
Payam Nahid, MD, MPH
Professor of Medicine, University of California, San Francisco
Director, UCSF Center for Tuberculosis
Co-Director, UCSF-UC Berkeley Tuberculosis Research Advancement Center (UC TRAC)
Director, Clinical Trials Operations, UCSF Office of Research
Medical Director, UCSF CTSI Trials Innovation Network (TIN)
Payam Nahid, MD, MPH, is a Professor in the Division of Pulmonary and Critical Care Medicine, Director of the UCSF Center for Tuberculosis, Co-Director of the UCSF-UC Berkeley Tuberculosis Research Advancement Center, Director of Clinical Trials Operations in the UCSF Office of Research, and Medical Director of the UCSF CTSA Trials Innovation Network Hub. His research includes the conduct of clinical trials and translational research in TB, and he leads NIH-funded field studies of new TB diagnostics, Phase 2 and 3 clinical trials in TB therapeutics and latent TB infection treatment implementation studies. Dr. Nahid serves as the Senior Scientific Advisor to the USAID-funded SMART4TB Consortium and led the WHO Task Force for New TB Drugs and Treatment Regimens, chairing the development of U.S. and international practice guidelines for the treatment of TB. Dr. Nahid serves as Vice Chair of the TB Transformative Science Group of the NIH ACTG, is a member of the ACTG leadership, and serves on the Scientific Agenda Steering Committee. Dr. Nahid was Co-Chair of the 2021 Phase 3 4-month rifapentine-based short-course treatment regimen and oversees NIH and BMGF-funded TB biomarker discovery and qualification programs to identify improved biomarkers of treatment effect.